

**UNITED STATES BANKRUPTCY COURT
SOUTHERN DISTRICT OF NEW YORK**

In re:

PURDUE PHARMA L.P., *et al.*,

Debtors.¹

Chapter 11

Case No. 19-23649 (RDD)

(Jointly Administered)

**FOURTEENTH MONTHLY FEE STATEMENT OF FTI CONSULTING, INC. FOR
COMPENSATION FOR SERVICES RENDERED AND REIMBURSEMENT OF
EXPENSES INCURRED AS FINANCIAL ADVISOR TO THE AD HOC COMMITTEE
OF GOVERNMENTAL AND OTHER CONTINGENT LITIGATION CLAIMANTS FOR
THE PERIOD FROM NOVEMBER 1, 2020 THROUGH NOVEMBER 30, 2020**

Name of Applicant:	FTI Consulting, Inc.
Authorized to provide Professional Services to:	Ad Hoc Committee of Governmental and Other Contingent Litigation Claimants
Date of Order Approving Debtors' Payment of Fees and Expenses of Applicant:	December 2, 2019 [ECF No. 553]
Period for which compensation and reimbursement is sought:	November 1, 2020 through November 30, 2020
Monthly Fees Incurred:	\$450,827.00

1. The Debtors in these chapter 11 cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifesciences Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717), and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

Monthly Expenses Incurred: \$0.00

Total Fees and Expenses Due: \$450,827.00

This is a: X monthly _____ interim _____ final application

PRIOR APPLICATIONS:

Docket No./Filed	Compensation Period	Requested		Approved	
		Fees	Expenses	Fees	Expenses
Docket No. 635 Filed On 12/9/2019	9/19/2019 – 10/31/2019	\$778,791.50	\$680.61	\$771,291.50	\$680.61
Docket No. 741 Filed On 1/13/2020	11/1/2019 – 11/30/2019	\$827,575.00	\$899.41	\$820,075.00	\$899.41
Docket No. 852 Filed on 2/20/2020	12/1/2019 – 12/31/2019	\$802,036.50	\$2,284.19	\$794,536.50	\$2,284.19
Docket No. 916 Filed on 3/12/2020	1/1/2020 – 1/31/2020	\$774,662.00	\$11,530.84	\$767,162.00	\$11,530.84
Docket No. 1090 Filed on 4/27/2020	2/1/2020 – 2/29/2020	\$615,089.00	\$6,141.22	\$610,714.00	\$6,141.22
Docket No. 1171 Filed on 5/19/2020	3/1/2020 – 3/31/2020	\$561,863.50	\$67.08	\$557,488.50	\$67.08
Docket No. 1251 Filed on 6/10/2020	4/1/2020 – 4/30/2020	\$428,303.00	\$1,732.28	\$423,928.00	\$1,732.28
Docket No. 1379 Filed on 7/13/2020	5/1/2020 – 5/31/2020	\$303,367.00	\$4,325.26	\$298,992.00	\$4,325.26
Docket No. 1651 Filed on 9/2/2020	6/1/2020 – 6/30/2020	\$374,753.00	\$96.90	\$372,253.00	\$ 96.90
Docket No. 1725 Filed on 9/25/2020	7/1/2020 – 7/31/2020	\$446,975.50	\$0.00	\$444,475.50	\$0.00
Docket No. 1850 Filed on 10/26/2020	8/1/2020 – 8/31/2020	\$261,092.00	\$108.25	\$258,592.00	\$108.25
Docket No. 1950 Filed on 10/26/2020	9/1/2020 – 9/30/2020	\$357,546.50	\$0.00	\$355,046.50	\$0.00
Docket No. 2154 Filed on 12/18/2020	10/1/2020 – 10/31/2020	\$356,078.50	\$0.00	\$ -	\$ -

Note: The fee examiner's agreed upon reductions of \$30,000, \$17,500, and \$10,000 were allocated evenly across fees from the first, second, and third interim period, respectively.

This statement (the "**Fee Statement**") of FTI Consulting, Inc. (together with its wholly owned subsidiaries and independent contractors, "**FTI**") as financial advisor to the Ad Hoc

Committee of Governmental and Other Contingent Litigation Claimants of Purdue Pharma L.P., *et al.* (the “**Committee**”) is submitted in accordance with the *Order Establishing Procedures for Interim Compensation and Reimbursement of Expenses for Retained Professionals* [ECF No. 529] and the *Order Authorizing the Debtors to Assume the Reimbursement Agreement and Pay the Fees and Expenses of the Ad Hoc Committee’s Professionals* [ECF No. 553] entered on November 21, 2019 and December 2, 2019, respectively, (the “**Orders**”). In support of this Fee Statement, FTI respectfully states as follows.

1. The fees and expenses for the period from November 1, 2020 through and including November 30, 2020 (the “**Fee Period**”) amount to:

Professional Fees	\$450,827.00
Expenses	<u>0.00</u>
TOTAL	<u>\$450,827.00</u>

2. In accordance with the Orders, FTI has separately recorded its fees in connection with or relating to the allocation of value among the Debtors’ creditors (the “**Allocation Fees**”) and has not, to the best of its knowledge, included Allocation Fees in this Fee Statement. If no timely and proper objection is made by a party-in-interest within fourteen (14) days after service of this Fee Statement, the Debtors are authorized to pay 80% of professional fees and 100% of out-of-pocket expenses. These amounts are presented below.

Professional Fees at 80%	\$360,661.60
Expenses at 100%	<u>0.00</u>
TOTAL	<u>\$360,661.60</u>

3. The professionals providing services, hourly billing rates, the aggregate hours worked by each professional, and the aggregate hourly fees for each professional during the Fee Period are set forth on the schedule annexed hereto as **Exhibit “A.”**

4. A summary of aggregate hours worked and aggregate hourly fees for each task code during the Fee Period is set forth on the schedule annexed hereto as **Exhibit “B.”**
5. Detailed time entry by task code during the Fee Period is set forth on the schedule annexed hereto as **Exhibit “C.”**
6. FTI reserves the right to request, in subsequent fee statements and applications, reimbursement of any additional expenses incurred during the Fee Period, as such expenses may not have been captured to date in FTI’s billing system.

NOTICE AND OBJECTION PROCEDURES

7. Objections to this Fee Statement, if any, must be filed with the Court and served upon the Notice Parties so as to be received no later than February 3, 2021 (the “**Objection Deadline**”), setting forth the nature of the objection and the amount of fees or expenses at issue (an “**Objection**”).
8. If no objections to this Fee Statement are filed and served as set forth above, the Debtors shall promptly pay eighty percent (80%) of the fees and one hundred percent (100%) of the expenses identified herein.
9. If an objection to this Fee Statement is received on or before the Objection Deadline, the Debtors shall withhold payment of that portion of this Fee Statement to which the objection is directed and promptly pay the remainder of the fees and disbursements in the percentages set forth above. To the extent such an objection is not resolved, it shall be preserved and scheduled for consideration at the next interim fee application hearing to be heard by the Court.

Dated: New York, New York
January 20, 2021

FTI CONSULTING, INC.
Financial Advisors to the Ad Hoc Committee of
Governmental and Other Contingent Litigation
Claimants of Purdue Pharma L.P.

By: /s/ Matthew Diaz
Matthew Diaz, Senior Managing Director
Three Times Square, 10th Floor
New York, New York 10036
Telephone: (212) 499-3611
Email: matt.diaz@fticonsulting.com

EXHIBIT A

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

SUMMARY OF HOURS BY PROFESSIONAL

FOR THE PERIOD NOVEMBER 1, 2020 TO NOVEMBER 30, 2020

Professional	Position	Specialty	Billing Rate¹	Total Hours	Total Fees
Diaz, Matthew	Senior Managing Director	Restructuring	\$ 1,085	95.0	\$ 103,075.00
Joffe, Steven	Senior Managing Director	Tax	1,125	11.0	12,375.00
Simms, Steven	Senior Managing Director	Restructuring	1,295	7.1	9,194.50
Bradley, Adam	Senior Managing Director	International Healthcare	1,160	3.0	3,480.00
Blonder, Brian	Managing Director	Intellectual Property	750	93.0	69,750.00
Suric, Emil	Senior Director	Healthcare	820	9.2	7,544.00
Bromberg, Brian	Director	Restructuring	815	167.7	136,675.50
Kim, Ye Darm	Senior Consultant	Restructuring	560	170.6	95,536.00
Kurtz, Emma	Consultant	Restructuring	415	31.8	13,197.00
GRAND TOTAL				588.4	\$ 450,827.00

1. Reflects blended hourly rates. Billing rates of international professionals have been translated to USD using the relevant spot rate.

EXHIBIT B

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

SUMMARY OF HOURS BY TASK

FOR THE PERIOD NOVEMBER 1, 2020 TO NOVEMBER 30, 2020

Task Code	Task Description	Total Hours	Total Fees
1	Current Operating Results & Events	9.2	\$ 5,225.00
7	Analysis of Domestic Business Plan	103.7	\$ 80,144.50
8	Valuation and Related Matters	0.6	\$ 651.00
9	Analysis of Employee Comp Programs	5.5	\$ 4,005.50
10	Analysis of Tax Issues	23.8	\$ 23,740.00
11	Prepare for and Attend Court Hearings	0.5	\$ 542.50
13	Analysis of Other Miscellaneous Motions	1.5	\$ 1,627.50
16	Analysis, Negotiate and Form of POR & DS	123.0	\$ 97,546.50
18	Review of Historical Transactions	250.5	\$ 187,798.50
19	Case Management	13.4	\$ 8,210.00
21	General Meetings with Counsel and/or Ad Hoc Committee	3.9	\$ 3,601.50
22	Meetings with Other Parties	2.0	\$ 2,170.00
24	Preparation of Fee Application	6.6	\$ 4,063.50
28	Review of IAC Business Plan	44.2	\$ 31,501.00
GRAND TOTAL¹		588.4	\$ 450,827.00

1. Billing rates of international professionals have been translated to USD using the relevant spot rate.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD NOVEMBER 1, 2020 TO NOVEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
1	11/2/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	11/3/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	11/4/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	11/5/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	11/6/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	11/9/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	11/10/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	11/11/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	11/12/2020	Kurtz, Emma	0.5	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	11/13/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	11/15/2020	Diaz, Matthew	0.5	Review of the July operating results.
1	11/16/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	11/17/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	11/18/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	11/18/2020	Diaz, Matthew	0.5	Review the 3rd monitor report.
1	11/18/2020	Diaz, Matthew	1.1	Review the Debtors' presentation on the domestic September YTD results.
1	11/19/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	11/20/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	11/23/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	11/24/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	11/25/2020	Kurtz, Emma	0.3	Correspond w/ Debtors' advisors re: clearance to share September YTD results with Committee.
1	11/25/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	11/30/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1 Total			9.2	
7	11/2/2020	Bromberg, Brian	0.5	Follow up on Rhodes Pipeline with Debtors.
7	11/2/2020	Kim, Ye Darm	0.4	Review PHI and Rhodes pipeline follow up requests.
7	11/5/2020	Kim, Ye Darm	0.6	Continue updating distributable value bridge to September business plan forecasts.
7	11/5/2020	Kim, Ye Darm	1.9	Prepare summary bridge of distributable value to September business plan forecasts.
7	11/5/2020	Kim, Ye Darm	1.3	Review historical OxyContin margins and prepare comparative analysis.
7	11/6/2020	Suric, Emil	0.9	Perform IMS data review for Rhodes pipeline forecasts.
7	11/6/2020	Kim, Ye Darm	1.1	Process revisions to the distributable value bridge to the September business plan forecasts.
7	11/6/2020	Kim, Ye Darm	1.6	Review segment level profitability forecasts re: cash flow analyses.
7	11/6/2020	Diaz, Matthew	1.3	Review the distributable value bridge to the Debtors' updated distributable value analysis.
7	11/9/2020	Suric, Emil	2.8	Perform Rhodes pipeline product due diligence analysis and sensitivity.
7	11/9/2020	Suric, Emil	2.2	Perform Rhodes pipeline product due diligence and sensitivity analysis.
7	11/9/2020	Bromberg, Brian	0.8	Review Rhodes pipeline product forecasts.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD NOVEMBER 1, 2020 TO NOVEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
7	11/9/2020	Bromberg, Brian	1.5	Review the Debtors' latest business plan presentation.
7	11/9/2020	Bromberg, Brian	1.9	Review the domestic business plan sensitivity scenarios.
7	11/10/2020	Bromberg, Brian	0.6	Discuss bridge analysis with Debtors.
7	11/10/2020	Bromberg, Brian	1.0	Discuss domestic business plan sensitivity assumptions with team.
7	11/10/2020	Diaz, Matthew	1.0	Review of the domestic business plan analysis and related case next steps.
7	11/10/2020	Kim, Ye Darm	1.2	Review Rhodes pipeline forecast analysis.
7	11/10/2020	Kim, Ye Darm	1.8	Review September business plan refresh presentation by the Debtors.
7	11/10/2020	Kim, Ye Darm	1.8	Update internal Rhodes pipeline forecast analysis for latest Debtor assumptions.
7	11/11/2020	Kim, Ye Darm	0.6	Process updates to OxyContin margin forecast comparative analysis.
7	11/11/2020	Bromberg, Brian	1.0	Review cash flow bridge analysis to Debtors' latest plan.
7	11/11/2020	Diaz, Matthew	0.5	Review of potential due diligence to be considered to be provided to a potential buyer.
7	11/11/2020	Kim, Ye Darm	0.4	Review Rhodes pipeline forecasts relative to managements' updated assumptions.
7	11/11/2020	Kim, Ye Darm	1.1	Update OxyContin margin forecast comparative analysis.
7	11/12/2020	Bromberg, Brian	0.8	Discuss domestic business plan sensitivity assumptions with team.
7	11/12/2020	Kim, Ye Darm	0.6	Participate in call re: domestic business plan sensitivities.
7	11/12/2020	Kurtz, Emma	1.9	Prepare analysis of YTD September domestic results to include in evaluation of business plan projections.
7	11/12/2020	Bromberg, Brian	1.8	Review domestic business plan sensitivity analyses.
7	11/12/2020	Diaz, Matthew	0.6	Review of the OxyContin margin forecast analysis.
7	11/12/2020	Kim, Ye Darm	0.7	Review OxyContin margin forecasts from the business plan.
7	11/12/2020	Kim, Ye Darm	0.9	Review September YTD results against business plan.
7	11/12/2020	Suric, Emil	0.5	Update Rhodes pipeline product sensitivities based on new data from client.
7	11/13/2020	Kim, Ye Darm	3.1	Prepare draft presentation re: domestic business plan sensitivities.
7	11/13/2020	Bromberg, Brian	2.8	Review domestic business plan sensitivities analysis slides.
7	11/13/2020	Bromberg, Brian	1.2	Review net distributable value bridge analysis to Debtors' latest business plan.
7	11/13/2020	Kim, Ye Darm	0.6	Review updated internal Rhodes pipeline forecasts analysis.
7	11/13/2020	Kim, Ye Darm	0.4	Update distributable value bridge to September forecasts for new cash savings.
7	11/14/2020	Kim, Ye Darm	1.5	Process revisions to presentation re: September business plan sensitivities.
7	11/15/2020	Bromberg, Brian	1.4	Prepare responses to questions on domestic business plan analysis.
7	11/15/2020	Diaz, Matthew	0.5	Review the Project Catalyst transaction and related impact on the business plan.
7	11/16/2020	Bromberg, Brian	0.5	Discuss cash flows analysis with PJT.
7	11/16/2020	Diaz, Matthew	1.0	Participate in a call with the Debtors to discuss revisions to the business plan.
7	11/16/2020	Kim, Ye Darm	1.0	Participate in call re: Purdue business plan projections.
7	11/16/2020	Bromberg, Brian	1.5	Prepare for Purdue internal team discussion.
7	11/16/2020	Kim, Ye Darm	2.1	Process revisions re: September business plan sensitivity analysis.
7	11/16/2020	Bromberg, Brian	1.0	Review domestic business plan sensitivity deck.
7	11/16/2020	Diaz, Matthew	0.9	Review the domestic business plan sensitivity analysis.
7	11/17/2020	Bromberg, Brian	0.6	Discuss domestic business plan sensitivities with Houlihan team.
7	11/17/2020	Kim, Ye Darm	1.8	Process revisions to presentation re: September business plan sensitivities.
7	11/17/2020	Kim, Ye Darm	1.5	Process revisions to the September business plan sensitivity considerations presentation.
7	11/17/2020	Diaz, Matthew	0.6	Review certain business plan materials being provided to a 3rd party.
7	11/17/2020	Bromberg, Brian	0.7	Review diligence materials to be provided to potential buyer.
7	11/17/2020	Bromberg, Brian	1.8	Review domestic business plan sensitivity analysis slides.
7	11/17/2020	Bromberg, Brian	1.0	Review domestic due diligence status with internal team.
7	11/17/2020	Suric, Emil	0.6	Update Rhodes pipeline product sensitivities for new data production.
7	11/18/2020	Bromberg, Brian	1.2	Review Rhodes pipeline and create request for Debtors.
7	11/19/2020	Bromberg, Brian	0.7	Continue review of the Rhodes pipeline and create request for Debtors.
7	11/19/2020	Bromberg, Brian	1.8	Discuss domestic cash flows analysis with internal team.
7	11/19/2020	Kim, Ye Darm	0.8	Review Rhodes pipeline product supporting files.
7	11/20/2020	Diaz, Matthew	0.7	Participate in a call with the Debtors to discuss the PHI.
7	11/20/2020	Bromberg, Brian	1.2	Participate in call with Debtors re: PHI.
7	11/20/2020	Bromberg, Brian	0.7	Participate in call with potential buyer.
7	11/23/2020	Bromberg, Brian	1.2	Create and review distributable value scenario cash flow assumptions.
7	11/23/2020	Bromberg, Brian	1.0	Discuss distributable value scenario with Houlihan.
7	11/23/2020	Bromberg, Brian	0.8	Discuss HL presentation re: distributable value cases with Houlihan.
7	11/23/2020	Bromberg, Brian	1.2	Participate in call with team re: distributable value scenario distributable value.
7	11/23/2020	Bromberg, Brian	2.3	Review and discuss core only business plan scenario.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD NOVEMBER 1, 2020 TO NOVEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
7	11/23/2020	Bromberg, Brian	1.7	Review and edit distributable value scenario cash flow assumptions.
7	11/23/2020	Bromberg, Brian	0.5	Review and finalize cash flow bridge analysis.
7	11/24/2020	Diaz, Matthew	2.6	Detail review of the updated business plan slides for the AHC.
7	11/24/2020	Bromberg, Brian	0.6	Discuss distributable value numbers and related assumptions with Houlihan.
7	11/24/2020	Bromberg, Brian	0.8	Discuss distributable value numbers and related assumptions with the Debtors.
7	11/24/2020	Bromberg, Brian	0.7	Discuss distributable value scenario presentation with team.
7	11/24/2020	Suric, Emil	0.5	Participate in discussions on due diligence findings for OxyContin.
7	11/24/2020	Bromberg, Brian	1.6	Review forecasts and assumptions for distributable value numbers versus public benefit cash flows.
7	11/24/2020	Bromberg, Brian	0.5	Review latest business plan sensitivities presentation.
7	11/24/2020	Bromberg, Brian	0.7	Review new distributable value scenario presentation slides.
7	11/24/2020	Diaz, Matthew	0.6	Review of the updated OxyContin sensitivity analysis.
7	11/24/2020	Bromberg, Brian	1.0	Review operating cash flow assumptions.
7	11/24/2020	Bromberg, Brian	0.8	Review OxyContin forecast assumptions for scenario analysis.
7	11/25/2020	Bromberg, Brian	0.6	Review Houlihan presentation re: strategic alternatives.
7	11/25/2020	Diaz, Matthew	1.1	Review of the business plan materials provided to potential buyer.
7	11/25/2020	Suric, Emil	1.1	Review OxyContin sensitivities performed, methodology relied on and produce support for generic conversation rate assumptions used.
7	11/25/2020	Bromberg, Brian	0.7	Review PEO information in slides for clearance.
7	11/29/2020	Diaz, Matthew	1.9	Review the updated presentation on the business plan and the distributable value analysis.
7	11/30/2020	Bromberg, Brian	1.7	Create diligence request list for Debtors.
7	11/30/2020	Bromberg, Brian	0.5	Participate in discussion re: OxyContin forecast with internal team.
7	11/30/2020	Bromberg, Brian	1.3	Participate in meeting with Debtors re: PHI status.
7	11/30/2020	Diaz, Matthew	1.3	Participate on call with Debtors re: the PHI program.
7	11/30/2020	Suric, Emil	0.6	Perform research on ANDA timelines.
7	11/30/2020	Kim, Ye Darm	1.0	Review dataroom documents to identify decline curve forecasts.
7 Total			103.7	
8	11/6/2020	Diaz, Matthew	0.6	Review of the Houlihan analysis re: potential buyer bid.
8 Total			0.6	
9	11/2/2020	Kim, Ye Darm	1.1	Analyze proposed UCC compensation adjustment analysis figures to prior compensation.
9	11/2/2020	Bromberg, Brian	1.3	Continue to review KEIP proposals analysis by UCC.
9	11/2/2020	Kim, Ye Darm	0.8	Prepare responses re: questions on UCC's proposed CEO compensation.
9	11/2/2020	Bromberg, Brian	0.7	Review KEIP proposals by UCC.
9	11/2/2020	Kim, Ye Darm	0.5	Review UCC proposed CEO Compensation reductions.
9	11/3/2020	Bromberg, Brian	0.6	Review KEIP proposals and correspond with Counsel.
9	11/3/2020	Diaz, Matthew	0.5	Review proposed Landau compensation adjustments by the UCC.
9 Total			5.5	
10	11/5/2020	Bromberg, Brian	0.5	Participate in call with Debtor Advisors re: IAC tax considerations.
10	11/5/2020	Joffe, Steven	1.0	Participate in call with KPMG and Counsel regarding IAC tax considerations.
10	11/5/2020	Bromberg, Brian	1.0	Participate in IAC tax call with KPMG and Counsel.
10	11/9/2020	Bromberg, Brian	0.8	Coordinate tax discussions with Debtors.
10	11/12/2020	Bromberg, Brian	0.9	Participate in call AHC tax counsel re: IAC tax considerations.
10	11/12/2020	Joffe, Steven	2.8	Participate in call with AHC and Debtors re: tax structuring considerations.
10	11/12/2020	Joffe, Steven	0.7	Participate in meeting with AHC re: tax considerations.
10	11/12/2020	Diaz, Matthew	0.8	Participate in tax call with the AHC tax advisors to discuss go forward and IAC tax issues.
10	11/13/2020	Diaz, Matthew	0.5	Participate in a tax call with the Debtors to discuss go forward tax implications.
10	11/13/2020	Kim, Ye Darm	1.0	Participate in call re: domestic business tax considerations.
10	11/13/2020	Bromberg, Brian	0.8	Participate in call re: domestic tax considerations call.
10	11/13/2020	Bromberg, Brian	1.1	Participate in call with Counsel re: IAC tax considerations call.
10	11/13/2020	Joffe, Steven	1.5	Participate in call with counsel re: tax structuring considerations.
10	11/13/2020	Bromberg, Brian	0.5	Review prior presentations to prepare for tax calls.
10	11/19/2020	Joffe, Steven	0.9	Participate in discussion with KPMG regarding IAC tax considerations.
10	11/19/2020	Bromberg, Brian	1.0	Participate in tax call with KPMG re: IAC tax considerations.
10	11/23/2020	Joffe, Steven	0.2	Review latest term sheets for tax implications.
10	11/29/2020	Diaz, Matthew	1.8	Review KPMG's updated tax analysis.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD NOVEMBER 1, 2020 TO NOVEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
10	11/30/2020	Bromberg, Brian	0.8	Participate in meeting re: KPMG tax analysis.
10	11/30/2020	Joffe, Steven	0.9	Participate in meeting re: KPMG tax analysis.
10	11/30/2020	Diaz, Matthew	1.3	Review KPMG's updated tax analysis.
10	11/30/2020	Joffe, Steven	3.0	Review KPMG's updated tax analysis.
10 Total			23.8	
11	11/18/2020	Diaz, Matthew	0.5	Review detailed correspondence on the DOJ court hearing.
11 Total			0.5	
13	11/12/2020	Diaz, Matthew	0.6	Review objections/statements re: the DOJ settlement.
13	11/12/2020	Diaz, Matthew	0.6	Review the UCC statement on the DOJ motion.
13	11/13/2020	Diaz, Matthew	0.3	Review the DOJ letter in response to various objections.
13 Total			1.5	
16	11/1/2020	Diaz, Matthew	0.6	Review the updated trust structuring presentation.
16	11/2/2020	Simms, Steven	0.4	Participate on DOJ call re: plan structure issues.
16	11/2/2020	Diaz, Matthew	1.9	Review the updated cash distribution analysis.
16	11/3/2020	Kim, Ye Darm	0.6	Continue processing revisions to the updated distributable value analysis.
16	11/3/2020	Simms, Steven	1.6	Participate in call with DOJ on settlement structure.
16	11/3/2020	Bromberg, Brian	1.1	Participate in call with DOJ re: emergence structure.
16	11/3/2020	Bromberg, Brian	1.5	Perform detailed QC re: cash flow analysis on distribution structure.
16	11/3/2020	Kim, Ye Darm	2.3	Prepare updated illustrative distributable value analysis based on latest figures.
16	11/3/2020	Kim, Ye Darm	0.8	Process revisions to the updated distributable value analysis.
16	11/3/2020	Bromberg, Brian	2.5	Review cash flow analysis on distributable value.
16	11/3/2020	Kim, Ye Darm	0.8	Review draft of HL structure and economic considerations presentation.
16	11/3/2020	Diaz, Matthew	1.1	Review the updated distributable value allocation model.
16	11/4/2020	Bromberg, Brian	1.4	Devise bridge on updated structuring numbers.
16	11/4/2020	Diaz, Matthew	1.0	Participate in a call with counsel to discuss the post emergence structure.
16	11/4/2020	Simms, Steven	0.7	Participate in AHC presentation re: deal structure.
16	11/4/2020	Kim, Ye Darm	1.1	Participate in call re: structuring and economic considerations presentation.
16	11/4/2020	Bromberg, Brian	0.9	Participate in discussion re: structuring financial information with internal team.
16	11/4/2020	Bromberg, Brian	1.0	Participate in structuring considerations call with AHC.
16	11/4/2020	Kim, Ye Darm	1.4	Prepare draft presentation slides re: updated net distributable value from structuring presentation.
16	11/4/2020	Kim, Ye Darm	2.3	Prepare scenario analyses re: updated net distributable value from structuring presentation.
16	11/4/2020	Kim, Ye Darm	1.3	Process revisions to the scenario analyses re: updated net distributable value from structuring presentation.
16	11/4/2020	Bromberg, Brian	0.8	Review assumptions behind structuring presentation figures.
16	11/4/2020	Bromberg, Brian	0.7	Review presentation slides on net distributable value scenarios.
16	11/5/2020	Kim, Ye Darm	0.7	Continue processing revisions to the net distributable value scenarios analysis and presentation.
16	11/5/2020	Bromberg, Brian	1.2	Continue revise assumptions re: distributable value bridging analysis.
16	11/5/2020	Kim, Ye Darm	0.4	Correspond with HL re: distributable value assumptions.
16	11/5/2020	Diaz, Matthew	1.0	Participate in a call with Counsel to discuss the updated term sheet.
16	11/5/2020	Kim, Ye Darm	1.1	Prepare revisions to the distributable value scenario analysis and presentation.
16	11/5/2020	Bromberg, Brian	1.2	Process revisions to slides re: net distributable value.
16	11/5/2020	Kim, Ye Darm	0.9	Process revisions to the distributable value scenario analysis and presentation.
16	11/5/2020	Diaz, Matthew	0.6	Review the updated settlement term sheet.
16	11/5/2020	Bromberg, Brian	2.3	Update distributable value bridge analysis.
16	11/5/2020	Kim, Ye Darm	0.4	Update term sheet figures in the distributable value scenarios.
16	11/6/2020	Kim, Ye Darm	0.9	Continue processing revisions of distributable value bridge to September business plan forecasts.
16	11/6/2020	Kim, Ye Darm	0.4	Correspond with HL re: distributable value assumptions.
16	11/6/2020	Bromberg, Brian	1.8	Finalize distributable value bridge and send to Debtors.
16	11/6/2020	Diaz, Matthew	0.6	Participate in a call with Houlihan to discuss potential strategic alternatives for the US business.
16	11/6/2020	Diaz, Matthew	1.0	Participate in a call with the AHC, NCSG and UCC professionals to discuss possible strategic alternatives.
16	11/6/2020	Bromberg, Brian	0.8	Participate in call with Houlihan re: potential strategic alternatives.
16	11/6/2020	Bromberg, Brian	1.0	Participate in call with UCC re: potential strategic alternatives.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD NOVEMBER 1, 2020 TO NOVEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
16	11/6/2020	Bromberg, Brian	0.6	Review the latest distributable value bridge analysis.
16	11/7/2020	Bromberg, Brian	0.8	Participate in call with UCC re: strategic alternatives.
16	11/9/2020	Kim, Ye Darm	0.6	Participate in call re: bid proposal.
16	11/9/2020	Bromberg, Brian	0.3	Participate in call re: potential strategic alternatives.
16	11/9/2020	Kim, Ye Darm	0.6	Review the bid proposal.
16	11/10/2020	Kim, Ye Darm	0.3	Correspond with HL re: mediation presentation.
16	11/10/2020	Kim, Ye Darm	0.5	Participate in call re: Bates White analysis.
16	11/10/2020	Kim, Ye Darm	0.6	Participate in call re: PBC Case cash flow assumptions.
16	11/10/2020	Kim, Ye Darm	0.8	Process updates to prior draft of mediation report.
16	11/10/2020	Bromberg, Brian	1.9	Review and process updates to mediation presentation.
16	11/10/2020	Simms, Steven	0.6	Review latest presentation materials re: Sackler settlement.
16	11/10/2020	Diaz, Matthew	0.8	Review the updated PBC cash flows and reconciliation analysis.
16	11/11/2020	Diaz, Matthew	0.7	Participate in a call with the AHC professionals to discuss strategic alternatives.
16	11/11/2020	Diaz, Matthew	1.1	Participate in a call with the MSGE group to discuss the mediation 2 presentation materials.
16	11/11/2020	Bromberg, Brian	1.2	Participate in call with MSGE re: mediation progress.
16	11/11/2020	Bromberg, Brian	0.5	Participate in call with team re: potential strategic alternatives.
16	11/11/2020	Kim, Ye Darm	1.0	Participate in call with the MSGE re: mediation progress.
16	11/11/2020	Bromberg, Brian	0.8	Participate in call with UCC re: potential strategic alternatives.
16	11/11/2020	Diaz, Matthew	0.5	Preparation for the call with the MSGE group re: mediation phase 2.
16	11/11/2020	Kim, Ye Darm	1.3	Process updates to net distributable value analysis per discussions with the Debtors.
16	11/11/2020	Bromberg, Brian	1.2	Review and process updates to the mediation presentation.
16	11/11/2020	Kim, Ye Darm	0.4	Review HL updates to draft of mediation presentation.
16	11/11/2020	Kim, Ye Darm	0.5	Review latest HL Governance presentation slides re: strategic considerations.
16	11/11/2020	Kim, Ye Darm	0.4	Review latest NDV scenario presentation by HL.
16	11/11/2020	Kim, Ye Darm	0.6	Review UCC statement re: DOJ settlement.
16	11/12/2020	Kim, Ye Darm	1.1	Correspond with HL re: distributable value assumptions and prepare responses to questions.
16	11/12/2020	Diaz, Matthew	0.3	Follow up call with the AHC professionals to discuss next steps and reactions to the call with the Debtors on the post emergence.
16	11/12/2020	Diaz, Matthew	2.4	Participate in a call with the Debtors and the AHC professionals to discuss the post emergence structure.
16	11/12/2020	Simms, Steven	0.6	Participate in call re: presentation re: emergence structure issues.
16	11/12/2020	Bromberg, Brian	2.2	Participate in call with Debtors re: post emergence structure.
16	11/12/2020	Kim, Ye Darm	2.5	Participate in call with the AHC re: structuring considerations.
16	11/12/2020	Bromberg, Brian	0.4	Participate in discussion re: sale process with Houlihan.
16	11/12/2020	Bromberg, Brian	0.6	Participate in post-call re: HL discussion debrief.
16	11/12/2020	Kim, Ye Darm	0.9	Review HL's support files re: no settlement scenarios.
16	11/12/2020	Simms, Steven	1.4	Review UCC presentation on settlement items.
16	11/13/2020	Kim, Ye Darm	1.1	Update distributions calculations re: net distributable value analysis with no settlement.
16	11/15/2020	Diaz, Matthew	0.9	Review the latest Purdue proposed term sheet.
16	11/16/2020	Simms, Steven	0.8	Review latest analyses re: Sackler settlement.
16	11/17/2020	Kim, Ye Darm	0.8	Participate in call with HL re: cash flow forecasts for distributable value.
16	11/18/2020	Bromberg, Brian	1.1	Participate in Committee call re: governance structure.
16	11/19/2020	Kim, Ye Darm	1.2	Process updates to September business plan cash flow bridge.
16	11/19/2020	Kim, Ye Darm	0.6	Review updated HL distributable value cash flow assumptions.
16	11/20/2020	Diaz, Matthew	0.5	Participate in a call with a 3rd party to discuss various strategic alternatives.
16	11/20/2020	Diaz, Matthew	1.5	Participate in a call with the AHC and the NCSG to discuss the go forward post emergence structure.
16	11/20/2020	Kim, Ye Darm	0.6	Participate in call with Debtors re: potential sale of assets.
16	11/20/2020	Bromberg, Brian	2.2	Participate in call with NCSG re: governance structure.
16	11/20/2020	Diaz, Matthew	0.6	Review the Purdue alternative plan structures legal analysis.
16	11/20/2020	Diaz, Matthew	0.7	Review the updated cash flow analysis and related due diligence.
16	11/22/2020	Diaz, Matthew	1.5	Participate in a call with the case key stakeholder financial advisers re: buyer due diligence.
16	11/23/2020	Diaz, Matthew	1.0	Participate in a call with Houlihan to discuss various distributable proceeds modeling scenarios.
16	11/23/2020	Kim, Ye Darm	1.0	Participate in call re: new optimized case cash flows.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD NOVEMBER 1, 2020 TO NOVEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
16	11/23/2020	Kim, Ye Darm	1.0	Participate in discussion with HL re: optimized CF scenario.
16	11/23/2020	Kim, Ye Darm	0.6	Participate in internal call re: updates to optimized cash flow assumptions.
16	11/23/2020	Kim, Ye Darm	1.1	Prepare analysis of optimized cash flows for distribution to Debtors and internal team.
16	11/23/2020	Kim, Ye Darm	2.3	Prepare cash flow bridge and assumptions for optimized cash flow case.
16	11/23/2020	Kim, Ye Darm	1.8	Process revisions to optimized case cash flow forecast assumptions.
16	11/23/2020	Kim, Ye Darm	0.9	Review diligence pack re: potential buyer bid.
16	11/23/2020	Kim, Ye Darm	0.9	Review HLs presentation re: cash flow cases for distributable value.
16	11/23/2020	Kim, Ye Darm	1.1	Review plan draft term sheet.
16	11/23/2020	Bromberg, Brian	2.7	Review plan term sheet and provide commentary.
16	11/23/2020	Diaz, Matthew	1.4	Review the proposed Purdue plan term sheet.
16	11/23/2020	Diaz, Matthew	1.5	Review various post emergence modeling sensitivities cases.
16	11/23/2020	Kim, Ye Darm	0.4	Update cash flow bridge analysis for latest assumptions.
16	11/24/2020	Diaz, Matthew	0.9	Participate in a call with Houlihan to discuss the updated distributable value presentation.
16	11/24/2020	Diaz, Matthew	0.8	Participate in a call with the Debtors to discuss the updated distributable value scenario.
16	11/24/2020	Kim, Ye Darm	0.5	Participate in call with Debtors re: optimized cash flow scenario assumptions.
16	11/24/2020	Simms, Steven	0.6	Participate in correspondence re: Sackler settlement issues.
16	11/24/2020	Kim, Ye Darm	1.9	Prepare summary slides for inclusion into HL's strategic options presentation.
16	11/24/2020	Kim, Ye Darm	1.1	Process additional revisions to summary slides for HL's strategic options presentation.
16	11/24/2020	Kim, Ye Darm	0.9	Process revisions to summary slides for HL's strategic options presentation.
16	11/24/2020	Bromberg, Brian	0.5	Review latest analysis re: Sackler professional fees estimates.
16	11/24/2020	Kim, Ye Darm	0.9	Update optimized cash flow case assumptions for asset sale proceeds.
16	11/25/2020	Kim, Ye Darm	1.0	Participate in call with AHC and NCSG re: settlement negotiations.
16	11/25/2020	Bromberg, Brian	0.7	Participate in call with NCSG re: settlement negotiations.
16	11/25/2020	Kim, Ye Darm	0.6	Review NCSG presentation to the Sacklers.
16	11/25/2020	Diaz, Matthew	1.2	Review the distributable value calculations in the AHC presentation.
16	11/30/2020	Diaz, Matthew	1.2	Participate in a call with the mediators and the Sacklers re the term sheet and related next steps.
16	11/30/2020	Kim, Ye Darm	1.1	Participate in discussion with Sackler counsel and AHC re: settlement negotiations.
16	11/30/2020	Bromberg, Brian	1.0	Participate in meeting with NCSG re: Sackler negotiations.
16	11/30/2020	Kim, Ye Darm	1.2	Participate in post call re: Sackler negotiations status.
16 Total			123.0	
18	11/2/2020	Blonder, Brian	2.1	Begin review of current Purdue license and other IP related agreements from data room.
18	11/2/2020	Bromberg, Brian	0.6	Discuss royalty analysis follow ups with internal team.
18	11/2/2020	Diaz, Matthew	1.0	Participate in a call with Province and Ocean Tomo to discuss the comps that they used for their non cash analysis.
18	11/2/2020	Bromberg, Brian	1.1	Participate in call with Ocean Tomo re: royalty analysis.
18	11/2/2020	Blonder, Brian	1.0	Participate in call with Ocean Tomo to discuss their royalty analysis presentation document.
18	11/2/2020	Bromberg, Brian	1.1	Participate in call with team on outstanding diligence items and workstreams for transfers analyses review.
18	11/2/2020	Blonder, Brian	0.8	Participate in discussion with IP team to discuss royalty rate analysis.
18	11/2/2020	Blonder, Brian	0.9	Prepare document request list re: Ocean Tomo royalty analysis.
18	11/2/2020	Bromberg, Brian	2.3	Prepare for internal call on outstanding diligence items re: royalty analysis.
18	11/2/2020	Kim, Ye Darm	2.2	Prepare skeleton presentation re: UCC transfer analysis review.
18	11/2/2020	Kim, Ye Darm	0.5	Review draft document request list re: cash/non-cash transfers analysis diligence.
18	11/2/2020	Bromberg, Brian	1.2	Review UCC transfer analysis and prepare diligence requests.
18	11/3/2020	Blonder, Brian	1.8	Continue review of full set of Purdue license and other IP related agreements.
18	11/3/2020	Diaz, Matthew	0.3	Participate in a call on the Ocean Tomo analysis with Province.
18	11/3/2020	Diaz, Matthew	0.3	Participate in a call with Counsel on the Ocean Tomo analysis and the Sackler transfers.
18	11/3/2020	Bromberg, Brian	1.4	Prepare refine diligence requests for Ocean Tomo re: royalty analysis.
18	11/3/2020	Blonder, Brian	0.8	Review Bates White "Non-Cash Transfer" Presentation.
18	11/3/2020	Diaz, Matthew	0.6	Review items owed from Ocean Tomo and related correspondence to the UCC.
18	11/3/2020	Diaz, Matthew	0.7	Review the Ocean Tomo analysis and related follow up questions coming out of the call with them.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD NOVEMBER 1, 2020 TO NOVEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
18	11/4/2020	Blonder, Brian	2.6	Continue review of full set of Purdue License and other agreements and create excel summary of information from agreements reviewed for royalty analysis.
18	11/4/2020	Blonder, Brian	0.9	Review analysis of OxyContin Sales by Country, Formulation and Year for royalty analysis.
18	11/4/2020	Blonder, Brian	1.2	Review Bates White preliminary transfer analysis 5/19 presentation document.
18	11/4/2020	Kim, Ye Darm	1.7	Review Bates White transfers analysis presentation and supporting forecast files.
18	11/4/2020	Bromberg, Brian	2.9	Review newly received diligence materials from Bates White.
18	11/5/2020	Blonder, Brian	2.1	Conduct preliminary review of database information for royalty agreements comparable to OxyContin.
18	11/5/2020	Blonder, Brian	0.6	Research OxyContin comparables for pharmaceutical industry royalty analysis.
18	11/6/2020	Blonder, Brian	2.6	Conduct preliminary review public information available for Ocean Tomo agreements with sales royalties.
18	11/6/2020	Blonder, Brian	1.9	Perform database search for Ocean Tomo referenced agreements focused contracts with royalties based on sales.
18	11/6/2020	Blonder, Brian	2.8	Perform preliminary inventory and rate and date review of database information for royalty analysis.
18	11/6/2020	Bromberg, Brian	0.8	Review prior mediation presentations for transfers related damages estimates.
18	11/9/2020	Bromberg, Brian	1.5	Participate in call with Bates White re: royalty analysis.
18	11/9/2020	Blonder, Brian	1.2	Participate in call with Bates White team to discuss their royalty analysis.
18	11/9/2020	Bromberg, Brian	2.0	Perform review Bates White diligence materials and analysis.
18	11/10/2020	Blonder, Brian	2.3	Create excel file summary of dates and royalty rates for agreements in database for OxyContin royalty comps.
18	11/10/2020	Blonder, Brian	0.9	Participate in call with IP team to discuss royalty analysis and follow-ups from the Bates White call.
18	11/10/2020	Bromberg, Brian	1.1	Participate in discussion re: transfers analysis with internal team.
18	11/10/2020	Bromberg, Brian	2.1	Prepare for transfers diligence workplan call with team.
18	11/10/2020	Diaz, Matthew	1.1	Review the Bates White report on the non-cash transfers.
18	11/10/2020	Kim, Ye Darm	0.7	Review transfer diligence request documents by the UCC.
18	11/11/2020	Blonder, Brian	5.2	Begin review of detailed summary of terms of selected key agreements from search of OxyContin comparables.
18	11/11/2020	Blonder, Brian	1.1	Review document containing information on OxyContin margins and profits.
18	11/11/2020	Diaz, Matthew	0.9	Review of the royalty rates benchmarks as compared to the Debtors' analysis.
18	11/12/2020	Blonder, Brian	4.7	Continue review of detailed summary of terms of selected key agreements from search of OxyContin comparables.
18	11/12/2020	Diaz, Matthew	1.9	Participate in a call with the states and the UCC to hear the UCC's presentation on potential causes of action.
18	11/12/2020	Bromberg, Brian	1.7	Participate in call with UCC re: causes of action.
18	11/12/2020	Kim, Ye Darm	1.4	Prepare revisions to UCC transfer analysis review presentation.
18	11/12/2020	Bromberg, Brian	1.3	Review outstanding diligence questions for Bates White.
18	11/13/2020	Bromberg, Brian	1.3	Participate in Bates White call re: transfer analysis.
18	11/13/2020	Kim, Ye Darm	1.1	Participate in call with Bates White re: transfer analysis.
18	11/13/2020	Bromberg, Brian	0.5	Participate in call with Counsel re: status of transfers diligence.
18	11/13/2020	Blonder, Brian	1.3	Participate in follow up call with Bates White to continue royalty analysis discussion.
18	11/13/2020	Diaz, Matthew	0.9	Participate in the non cash transfers call with Bates White.
18	11/13/2020	Bromberg, Brian	0.8	Prepare Bates White diligence request list.
18	11/13/2020	Bromberg, Brian	0.7	Review analyses and prior presentations to prepare for Bates White call re: transfer analyses.
18	11/13/2020	Blonder, Brian	0.3	Review analysis in preparation for call with Bates White.
18	11/13/2020	Blonder, Brian	0.8	Update excel analysis summarizing agreements from OxyContin comparable search.
18	11/14/2020	Kim, Ye Darm	1.6	Review draft question list re: Asset tracing and prepare initial responses.
18	11/15/2020	Diaz, Matthew	0.4	Participate in a call with Counsel re: the open items list re ability to collect potential litigation awards.
18	11/15/2020	Kim, Ye Darm	0.7	Participate in call re: asset tracing question initial responses.
18	11/15/2020	Kim, Ye Darm	0.6	Prepare updated asset tracing questions list for Counsel.
18	11/15/2020	Diaz, Matthew	0.7	Review ability to collect open items list and reconcile to related source documents.
18	11/15/2020	Bromberg, Brian	1.1	Review Sackler asset tracing diligence questions.
18	11/15/2020	Diaz, Matthew	1.5	Review the UCC presentation on the potential causes of action.
18	11/15/2020	Diaz, Matthew	1.1	Review the updated royalty rate analysis.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD NOVEMBER 1, 2020 TO NOVEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
18	11/16/2020	Blonder, Brian	4.1	Begin search to locate agreements listed by Ocean Tomo as comparable agreements and review information and agreements found.
18	11/16/2020	Bromberg, Brian	0.8	Finalize Bates White diligence questions list.
18	11/16/2020	Diaz, Matthew	1.1	Participate in a call with Counsel to discuss potential litigation against the Sacklers.
18	11/16/2020	Kim, Ye Darm	1.0	Participate in call re: asset tracing questions with Counsel.
18	11/16/2020	Bromberg, Brian	0.9	Participate in call re: Sackler asset tracing questions.
18	11/16/2020	Kim, Ye Darm	3.2	Prepare analysis of Sackler balance sheets by jurisdiction.
18	11/16/2020	Kim, Ye Darm	0.5	Process updates to Sackler balance sheet by jurisdiction analysis.
18	11/16/2020	Bromberg, Brian	0.9	Review FTI analysis of royalty agreements re: transfers analyses.
18	11/16/2020	Diaz, Matthew	0.5	Review info request list to the UCC re: questions on their causes of action report.
18	11/16/2020	Bromberg, Brian	1.4	Review status of Sackler assets based on materials provided.
18	11/17/2020	Blonder, Brian	5.9	Continue search to locate agreements listed by Ocean Tomo as comparable agreements and review information and agreements found.
18	11/17/2020	Bromberg, Brian	1.1	Continue to review files on situs of Sackler assets and trusts.
18	11/17/2020	Blonder, Brian	2.1	Create spreadsheet summarizing results of search for information on agreements relied on by Ocean Tomo.
18	11/17/2020	Kim, Ye Darm	0.3	Identify variances between trust net asset figures reported.
18	11/17/2020	Kim, Ye Darm	1.0	Participate in call re: B-side equity roll analysis.
18	11/17/2020	Kim, Ye Darm	0.6	Participate in call re: updated balance sheet summary analysis.
18	11/17/2020	Kim, Ye Darm	1.0	Participate in call w/ UCC re: avoidance actions.
18	11/17/2020	Bromberg, Brian	0.7	Participate in call with Huron re: Side B transfers.
18	11/17/2020	Kim, Ye Darm	1.6	Prepare abridged equity roll analysis.
18	11/17/2020	Kim, Ye Darm	2.1	Prepare abridged tracing analysis for Theresa Sackler related trust assets.
18	11/17/2020	Kim, Ye Darm	0.7	Prepare response re: trust asset variances between reports.
18	11/17/2020	Kim, Ye Darm	1.7	Prepare summary analysis of Sackler family trust balance sheets.
18	11/17/2020	Kim, Ye Darm	0.4	Process updates to balance sheet summary analysis.
18	11/17/2020	Bromberg, Brian	0.7	Review files on Sackler assets for call with Huron.
18	11/17/2020	Bromberg, Brian	1.0	Review files on situs of Sackler assets and trusts.
18	11/17/2020	Diaz, Matthew	1.5	Review the trust transfer analysis as requested by Counsel.
18	11/17/2020	Kim, Ye Darm	1.8	Review UCC Presentation re: avoidance actions.
18	11/18/2020	Kim, Ye Darm	0.6	Identify variances between internal and UCC net asset analyses.
18	11/18/2020	Kim, Ye Darm	0.5	Participate in call re: updates to equity roll analysis.
18	11/18/2020	Kim, Ye Darm	2.9	Prepare revisions to equity roll analysis per internal comments.
18	11/18/2020	Kim, Ye Darm	0.4	Process revisions to B-side equity roll analysis.
18	11/18/2020	Kim, Ye Darm	0.9	Process revisions to Sackler trust balance sheet analysis.
18	11/18/2020	Kim, Ye Darm	1.3	Process revisions to Theresa Sackler related trust asset abridged tracing analysis.
18	11/18/2020	Bromberg, Brian	1.8	Review analyses on situs of Sackler assets.
18	11/18/2020	Diaz, Matthew	0.6	Review diligence correspondence relating to the A and B side transfers.
18	11/18/2020	Diaz, Matthew	0.6	Review the Sackler trust asset analysis.
18	11/18/2020	Blonder, Brian	7.2	Search for information on agreements relied on Ocean Tomo in its loss of exclusivity analysis and creation of summary of information found.
18	11/19/2020	Blonder, Brian	1.5	Created file summarizing key highlights from review of Ocean Tomo agreements and related information.
18	11/19/2020	Kim, Ye Darm	0.4	Participate in discussion re: OxyContin royalty damages sensitivity model.
18	11/19/2020	Kurtz, Emma	1.6	Prepare analysis re: historical OxyContin royalties based on Bates White proposed royalty rates ranges.
18	11/19/2020	Kim, Ye Darm	2.9	Prepare model for OxyContin sensitivity calculations.
18	11/19/2020	Blonder, Brian	0.5	Process revisions to spreadsheets reviewing agreements relied upon by Ocean Tomo.
18	11/19/2020	Kim, Ye Darm	1.1	Process revisions to Theresa Sackler related trust asset abridged tracing analysis.
18	11/19/2020	Kurtz, Emma	0.4	Review Bates White report re: analysis of OxyContin royalty damages calculation.
18	11/19/2020	Kim, Ye Darm	1.8	Review historical royalty growth rates in UCC analysis against IAC supporting data.
18	11/19/2020	Bromberg, Brian	1.2	Review latest Bates White diligence materials and related analysis.
18	11/19/2020	Bromberg, Brian	2.2	Review royalties calculation on historical sales.
18	11/19/2020	Diaz, Matthew	0.6	Review the updated A side transfers analysis.
18	11/19/2020	Diaz, Matthew	0.9	Review the updated royalty damages analysis.
18	11/20/2020	Blonder, Brian	4.0	Begin review of agreements relied upon by Bates White to assess royalty rates.
18	11/20/2020	Bromberg, Brian	0.5	Discuss the asset transfers analyses with internal team.
18	11/20/2020	Bromberg, Brian	0.8	Participate in call with UCC re: collectability of assets.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD NOVEMBER 1, 2020 TO NOVEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
18	11/20/2020	Kim, Ye Darm	0.9	Participate in call with UCC re: transfer considerations.
18	11/20/2020	Kim, Ye Darm	1.9	Process updates to equity roll bridge analysis.
18	11/20/2020	Kim, Ye Darm	1.8	Process updates to Purdue trust balance sheet analysis and tie variance to UCC reports.
18	11/20/2020	Bromberg, Brian	1.3	Review asset situs files from UCC.
18	11/20/2020	Kim, Ye Darm	1.3	Review the UCC trust balance sheet asset analysis.
18	11/20/2020	Diaz, Matthew	0.4	Review the updated A-side transfers analysis.
18	11/20/2020	Diaz, Matthew	0.8	Review the updated B-side transfers analysis.
18	11/20/2020	Diaz, Matthew	0.7	Review the updated OxyContin royalty analysis.
18	11/20/2020	Kim, Ye Darm	0.6	Review UCC trust balance sheet asset diligence question list.
18	11/22/2020	Blonder, Brian	3.5	Continue review of agreements relied upon by Bates White.
18	11/22/2020	Bromberg, Brian	0.8	Prepare summary of call with Counsel re: collectability.
18	11/22/2020	Diaz, Matthew	0.7	Review collectability issues and discuss related next steps.
18	11/23/2020	Blonder, Brian	2.3	Add Bates White agreements description worksheet to file describing all agreements reviewed.
18	11/23/2020	Blonder, Brian	3.7	Begin review of additional OT comp agreements provided by Ocean Tomo.
18	11/23/2020	Blonder, Brian	3.3	Finish review of Bates White agreements received.
18	11/23/2020	Diaz, Matthew	0.9	Participate in a call with Counsel to discuss collectability considerations in connection with certain causes of action.
18	11/23/2020	Bromberg, Brian	0.7	Participate in call on collectability of Sackler assets.
18	11/23/2020	Kim, Ye Darm	0.6	Participate in call re: collectability considerations.
18	11/23/2020	Bromberg, Brian	0.8	Review collectability diligence files provided.
18	11/23/2020	Kim, Ye Darm	1.1	Review documents received re: Ocean Tomo's comparable agreements.
18	11/23/2020	Bromberg, Brian	0.7	Review Ocean Tomo comparable agreements.
18	11/23/2020	Kurtz, Emma	0.2	Review recently received diligence documents re: backup files to UCC transfers analysis to share with team.
18	11/23/2020	Diaz, Matthew	0.3	Review related documents in preparation for the call with Counsel re: collectability scenarios.
18	11/23/2020	Diaz, Matthew	1.1	Review the updated collectability analysis and related next steps.
18	11/24/2020	Blonder, Brian	2.1	Begin review of additional OT LOE agreements received from Ocean Tomo.
18	11/24/2020	Blonder, Brian	4.4	Finish review of additional OT comp agreements received from Ocean Tomo.
18	11/24/2020	Diaz, Matthew	0.5	Participate in a call with Huron to discuss the A-side requests.
18	11/24/2020	Bromberg, Brian	1.0	Participate in discussion re: latest work on Sackler assets with Huron.
18	11/24/2020	Kim, Ye Darm	1.8	Prepare asset tracing exercise for the MDAS Investment Trust.
18	11/24/2020	Kim, Ye Darm	3.1	Prepare draft presentation re: collectability considerations.
18	11/24/2020	Bromberg, Brian	3.3	Review the B-side asset transfer tracing analysis.
18	11/24/2020	Diaz, Matthew	0.7	Review the updated A-side transfer analysis.
18	11/24/2020	Kim, Ye Darm	1.1	Update Collectability presentation for executive summary and B-side analysis.
18	11/24/2020	Blonder, Brian	1.5	Update worksheet of OT comps to include descriptions of new OT comp agreements reviewed.
18	11/25/2020	Blonder, Brian	2.2	Add comments to set of agreements reviewed based on considerations for assessing comparables.
18	11/25/2020	Bromberg, Brian	0.8	Continue review and process revisions re: collectability considerations slides.
18	11/25/2020	Blonder, Brian	0.7	Create word file with summary of key considerations for assessing comparability of agreements
18	11/25/2020	Bromberg, Brian	0.5	Discuss latest royalties diligence status.
18	11/25/2020	Bromberg, Brian	1.1	Discuss workplan re: transfers analysis diligence.
18	11/25/2020	Blonder, Brian	2.2	Finish review of additional OT LOE agreements received from Ocean Tomo.
18	11/25/2020	Kim, Ye Darm	0.5	Participate in discussion re: royalties analysis.
18	11/25/2020	Kim, Ye Darm	0.6	Prepare sensitivity tables for damages calculations.
18	11/25/2020	Kim, Ye Darm	1.1	Prepare updated draft transfers analysis diligence presentation.
18	11/25/2020	Kim, Ye Darm	0.8	Process revisions to collectability presentation per internal comments.
18	11/25/2020	Kim, Ye Darm	0.9	Process revisions to presentation re: collectability considerations.
18	11/25/2020	Kim, Ye Darm	1.3	Process updates to OxyContin royalties sensitivity model.
18	11/25/2020	Bromberg, Brian	0.9	Review and process revisions re: collectability considerations slides.
18	11/25/2020	Kim, Ye Darm	1.2	Review Bates White calculation of royalty product contributions against historical figures.
18	11/25/2020	Kim, Ye Darm	1.3	Review dataroom for information on historical OxyContin patents.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD NOVEMBER 1, 2020 TO NOVEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
18	11/25/2020	Kurtz, Emma	0.3	Review historical royalty payments from the IACs and comparison to Debtors and UCC analysis.
18	11/25/2020	Kim, Ye Darm	0.6	Review IP team draft review of comparable royalty agreements.
18	11/25/2020	Bromberg, Brian	2.8	Review royalties damages calculation on historical sales.
18	11/25/2020	Diaz, Matthew	1.1	Review the collectability presentation for AHC counsel.
18	11/25/2020	Kim, Ye Darm	1.1	Review updated version of the Bates White Report.
18	11/25/2020	Blonder, Brian	0.9	Update OT LOE worksheet to add descriptions of additional agreements reviewed.
18	11/29/2020	Diaz, Matthew	1.3	Review and finalize the updated collectability presentation.
18	11/29/2020	Bromberg, Brian	0.5	Review royalties calculation on historical sales.
18	11/30/2020	Blonder, Brian	1.0	Participate in call re: royalty analysis workproduct and status.
18	11/30/2020	Kim, Ye Darm	1.0	Participate in discussion re: transfers diligence progress.
18	11/30/2020	Bromberg, Brian	1.0	Participate in meeting re: royalty comps.
18	11/30/2020	Bromberg, Brian	1.3	Participate in meeting with Sackler counsel re: asset information.
18	11/30/2020	Diaz, Matthew	1.4	Perform detailed review of the Bates White analysis of the non cash transfers.
18	11/30/2020	Kurtz, Emma	1.4	Prepare analysis of illustrative value of OxyContin rights transferred in 2017.
18	11/30/2020	Kurtz, Emma	0.6	Prepare revisions to analysis of illustrative value of OxyContin rights transferred in 2017.
18	11/30/2020	Kim, Ye Darm	0.4	Review draft list of Bates White transfers diligence questions.
18	11/30/2020	Bromberg, Brian	2.7	Review royalties calculation on historical sales.
18	11/30/2020	Diaz, Matthew	0.5	Review the non cash transfer diligence question list to Bates White.
18	11/30/2020	Diaz, Matthew	1.5	Review updated royalty rates and findings re: the Debtors' and UCC's analysis.
18 Total			250.5	
19	11/2/2020	Kurtz, Emma	0.8	Participate in call to discuss outstanding workstreams and upcoming deliverables.
19	11/2/2020	Kim, Ye Darm	0.8	Participate in discussion re: ongoing diligence workstreams.
19	11/2/2020	Kim, Ye Darm	0.6	Participate in follow-up discussion re: ongoing diligence workstreams.
19	11/5/2020	Kurtz, Emma	0.3	Review recently uploaded diligence documents to update dataroom index and distribute to team.
19	11/6/2020	Kurtz, Emma	0.4	Prepare revisions to dataroom index to include recently uploaded diligence documents.
19	11/10/2020	Kim, Ye Darm	1.0	Participate in call re: ongoing diligence workstreams.
19	11/10/2020	Kurtz, Emma	1.0	Participate in call to discuss project work plan and upcoming deliverables.
19	11/13/2020	Kurtz, Emma	0.4	Prepare updates to dataroom index to reflect recently received diligence documents to share with team.
19	11/16/2020	Bromberg, Brian	1.3	Discuss latest diligence workstreams with internal team.
19	11/16/2020	Kim, Ye Darm	1.2	Participate in call re: outstanding workstreams.
19	11/16/2020	Kurtz, Emma	1.3	Participate in call to review workplan and identify upcoming deliverables.
19	11/16/2020	Diaz, Matthew	0.9	Review case open items and plan related next steps for workstreams.
19	11/17/2020	Simms, Steven	0.4	Participate in correspondence re: follow-ups from hearing.
19	11/25/2020	Kim, Ye Darm	0.8	Participate in discussion re: ongoing diligence workstreams.
19	11/25/2020	Kurtz, Emma	0.7	Participate on call to discuss outstanding case items and upcoming deliverables, including transfers analysis and asset reports.
19	11/25/2020	Diaz, Matthew	0.8	Review case open items and plan related next steps for workstreams.
19	11/30/2020	Kurtz, Emma	0.7	Prepare updates to dataroom index to incorporate recently received diligence documents to share with team.
19 Total			13.4	
21	11/13/2020	Diaz, Matthew	0.5	Participate in a call with AHC counsel to discuss open due diligence and related next steps.
21	11/18/2020	Diaz, Matthew	1.5	Participate in a committee call to discuss the go forward plan structure.
21	11/18/2020	Kim, Ye Darm	1.2	Participate in AHC call re: governance considerations.
21	11/30/2020	Diaz, Matthew	0.7	Participate in a call with the AHC and the NCSG to discuss our call with the mediators.
21 Total			3.9	
22	11/3/2020	Diaz, Matthew	2.0	Participate in a presentation with the AHC and the DOJ to discuss post emergence structure.
22 Total			2.0	
24	11/3/2020	Kim, Ye Darm	1.1	Finalize draft of third interim fee application.
24	11/3/2020	Kim, Ye Darm	0.6	Prepare fee and expense detail for fee examiner.
24	11/6/2020	Diaz, Matthew	0.7	Review of the allocation fee statement.
24	11/13/2020	Kim, Ye Darm	0.3	Finalize the September Fee Application.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD NOVEMBER 1, 2020 TO NOVEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
24	11/16/2020	Kim, Ye Darm	0.3	Finalize third interim bill.
24	11/18/2020	Kim, Ye Darm	0.8	Prepare fee app support for fee examiner.
24	11/30/2020	Kim, Ye Darm	2.8	Prepare the October fee app.
24 Total			6.6	
28	11/2/2020	Diaz, Matthew	0.6	Participate in a call with the IACs to discuss open due diligence.
28	11/2/2020	Bromberg, Brian	0.6	Participate in call with IAC management re: YTD performance.
28	11/2/2020	Kurtz, Emma	1.9	Prepare summary analysis of product-level P&L information to evaluate business plan projections by entity.
28	11/2/2020	Kurtz, Emma	1.2	Prepare summary analysis of revised product-level P&L to evaluate EBITDA contribution by product by entity.
28	11/3/2020	Kurtz, Emma	1.3	Continue to prepare detailed analysis of country and product-level diligence responses received from the Company in preparation for review of revised business plan projections.
28	11/3/2020	Kurtz, Emma	2.6	Prepare detailed analysis of country and product-level diligence responses received from the Company in preparation for review of revised business plan projections.
28	11/3/2020	Kurtz, Emma	0.6	Review diligence responses from the Company and the September IAC sales updates re: evaluation of progress against business plan projections.
28	11/3/2020	Kim, Ye Darm	1.1	Review YTD financial presentations re: IACs.
28	11/4/2020	Kurtz, Emma	1.4	Incorporate relevant product sales information exhibits provided by the Company into the consolidated diligence responses to prepare for business plan projections review.
28	11/4/2020	Kurtz, Emma	1.6	Prepare revisions to summary analysis of product-level P&L information and related diligence responses re: analysis of revised business plan projections.
28	11/4/2020	Bromberg, Brian	1.1	Review IAC OxyContin sales forecast information.
28	11/4/2020	Bradley, Adam	3.0	Review IAC YTD performance per management's presentation.
28	11/4/2020	Kim, Ye Darm	1.2	Review summary of country-level business plan diligence responses.
28	11/5/2020	Diaz, Matthew	0.5	Participate in a call with Alix to discuss the IAC tax analysis.
28	11/5/2020	Diaz, Matthew	1.0	Participate in a call with the UCC, Debtor and AHC advisors to discuss the IAC tax situation.
28	11/5/2020	Kim, Ye Darm	1.0	Participate in call re: IAC tax considerations.
28	11/6/2020	Bromberg, Brian	0.6	Participate in IAC deposition call.
28	11/6/2020	Bromberg, Brian	0.4	Review IAC information to prepare for IAC deposition call.
28	11/9/2020	Bromberg, Brian	1.1	Review IAC summary financial files.
28	11/10/2020	Bromberg, Brian	1.9	Continue review of IAC summary financial files.
28	11/10/2020	Kurtz, Emma	0.9	Prepare revisions to country level diligence responses analysis to incorporate internal comments.
28	11/10/2020	Kim, Ye Darm	1.1	Review IAC product P&L information for historical margin information.
28	11/11/2020	Bromberg, Brian	1.1	Continue review of IAC summary financial files.
28	11/11/2020	Bromberg, Brian	0.9	Participate in discussion re: historical IAC product margins with team.
28	11/11/2020	Bromberg, Brian	1.8	Perform review of historical IAC product margins.
28	11/11/2020	Kurtz, Emma	0.8	Prepare revisions to summary analysis of revised product P&L to reflect internal comments.
28	11/11/2020	Kim, Ye Darm	1.0	Review updated analysis re: IAC product P&L and diligence responses.
28	11/12/2020	Kim, Ye Darm	1.0	Participate in prep call re: IAC tax considerations.
28	11/13/2020	Diaz, Matthew	1.1	Participate in a tax call with the key case advisors to discuss the tax implications of an IAC sale including various sensitivities.
28	11/13/2020	Kim, Ye Darm	1.0	Participate in call re: IAC business tax considerations.
28	11/13/2020	Diaz, Matthew	0.8	Review of the Purdue YTD performance reports.
28	11/16/2020	Kim, Ye Darm	1.1	Review IAC audited historical financial statements.
28	11/16/2020	Diaz, Matthew	1.6	Review the IAC audited financial statements.
28	11/16/2020	Bromberg, Brian	1.7	Review the IAC audited financial statements.
28	11/19/2020	Diaz, Matthew	0.8	Participate in a call with the tax professionals re: IAC tax considerations and scenarios.
28	11/20/2020	Diaz, Matthew	0.9	Continue review of the IAC audited financial statements.
28	11/20/2020	Bromberg, Brian	0.4	Discuss IAC financials with team and prepare list of diligence questions.
28	11/20/2020	Kurtz, Emma	0.4	Review audited historical financials for 2016 through 2018 to compare to the latest Malta model historical financial results.
28	11/20/2020	Kim, Ye Darm	1.1	Review historical financial statements for 2016-2018 and tie with existing financial information.

EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

DETAIL OF TIME ENTRIES

FOR THE PERIOD NOVEMBER 1, 2020 TO NOVEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
28 Total			44.2	
GRAND TOTAL			588.4	